Results 71 to 80 of about 55,011 (304)

Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. [PDF]

, 2014
Background: Rodents are incapable of emesis and consequently the emetic potential of glucagon-like peptide-1 receptor (GLP-1R) agonists in studies designed to assess a potential blood glucose lowering action of the compound was missed.
A Amato, A Flint, A Rotondo, A Vella, A Wettergren, AD Farmer, AH Barnett, AM Holmes, B Kreymann, BD Kiernan, BP Bullock, C Tourrel, CA Richards, Chi-Kong Yeung, CM Edwards, CR Abbott, David TW Yew, DD De Leon, Ge Lin, GJ Sanger, GM Holmes, GR Morrow, I Billig, I Doweck, INC Lawes, J Kim, JA Kim, JL Iltz, JL Lachey, JM Egan, John A Rudd, JP Gutzwiller, JP Gutzwiller, JP Gutzwiller, K Venkova, KE Mayo, KP Kinzig, L Van Bloemendaal, L Zheng, LL Baggio, LT LaCount, M Reardon, MM Combettes, N Imeryuz, N Percie Du Sert, N Percie du Sert, N Percie Du Sert, NA Gupta, Nathalie Percie Du Sert, NH Greig, P Bhandari, Paul LR Andrews, PJ Gianaros, PJ Shughrue, PL Andrews, R Goke, R Goke, R Shirazi, RM Stern, S Madsbad, SE Ayachi, SE Kanoski, SW Chan, SW Chan, SW Chan, Sze Wa Chan, T Perry, T Tolessa, T Tolessa, V Bucinskaite, Y Wei, Zengbing Lu   +71 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Review article: a comparison of glucagon-like peptides 1 and 2. [PDF]

, 2013
BACKGROUND: Recent advancements in understanding the roles and functions of glucagon-like peptide 1 (GLP-1) and 2 (GLP-2) have provided a basis for targeting these peptides in therapeutic strategies.
Amato, Amato, Amato, Amin, Andrews, Andrews, Angelone, Anini, Anvari, Au, Baggio, Baggio, Bahrami, Baldassano, Baldassano, Bengi, Benjamin, Bjerknes, Blomgren, Booth, Bose, Boushey, Boushey, Bremholm, Brubaker, Brubaker, Brubaker, Brubaker, Buchman, Bucinskaite, Bullock, Buse, Caddy, Cameron, Cameron, Campos, Cani, Chance, Cheeseman, Cinci, Cummings, Daniel, Deacon, Deacon, Delgado-Aros, Drucker, Drucker, Drucker, Drucker, Drucker, Drucker, Drucker, Drucker, Dube, Dube, Dube, Dunphy, Estall, Farilla, Fehmann, Flint, Garber, Giralt, Goke, Guan, Guan, Gutzwiller, Gutzwiller, Hadjiyanni, Hansen, Hansen, Hargrove, Hartmann, Herrmann, Holst, Holst, Hornby, Hsieh, Hui, Iakoubov, Imeryuz, Iwai, Jeppesen, Jeppesen, Jeppesen, Jeppesen, Jeppesen, Johansen, Kato, Kendall, Kieffer, Kim, Kim, Knauf, Knudsen, Koehler, Koehler, Koopmann, Koopmann, Kunkel, Leen, Li, Lim, Linnebjerg, Liu, Liu, Lovshin, Lovshin, Lovshin, Madsbad, Marre, Martin, Martin, McDonagh, Meier, Meier, Miki, Moretto, Munroe, Nagell, Nakagawa, Naslund, Naslund, Nauck, Nelson, Nelson, Nielsen, Nikolaidis, Nystrom, Orskov, Orskov, Orskov, Orskov, Orskov, Orskov, Parks, Peters, Petersen, Petersen, Petersen, Pinelli, Portha, Reimann, Reimann, Roberge, Rocca, Rotondo, Rouille, Rowland, Rowland, Ruiz-Grande, Schirra, Schmidt, Schmidt, Schwartz, Scott, Shin, Sigalet, Sigalet, Sinclair, Skarbaliene, Sorensen, Stephens, Sturis, Tanaka, Tang-Christensen, Tang-Christensen, Tavares, Tee, Thong, Thulesen, Thulesen, Tolessa, Tolessa, Tornehave, Trivedi, Tsai, Tsai, Ugleholdt, Velazquez, Velazquez, Verdich, Voss, Vrang, Wallis, Wallis, Washizawa, Wettergren, Wettergren, Wheeler, Wideman, Wishart, Wojdemann, Wojdemann, Xiao, Xiao, Xu, Yamamoto, Yamazaki, Yusta, Yusta, Zhu, Zinman   +202 more
core   +1 more source

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes:a substudy of the SUSTAIN 8 randomised, controlled clinical trial [PDF]

, 2020
Aims/hypothesis: Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a ...
Catarig, Andrei-Mircea, Frias, Juan P., Lausvig, Nanna L., le Roux, Carel W., Lingvay, Ildiko, McCrimmon, Rory, Thielke, Desirée   +6 more
core   +2 more sources

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes

Journal of Diabetes Investigation
Aims To evaluate characteristics and glycemic outcomes in individuals with type 2 diabetes using injectable therapies in real‐world clinical practice in Tianjin, China.
Qiumei Zhang, Yaqing Fan, Xixi Liu, Minlu Zhang, Jiewen Zhang, Qin Du, Lei Kang, Liming Chen   +7 more
doaj   +1 more source

Microbiota-Produced N-Formyl Peptide fMLF Promotes Obesity-Induced Glucose Intolerance. [PDF]

, 2019
The composition of the gastrointestinal microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose ...
Chan, Luisa S, Chordia, Mahendra D, El Ouarrat, Dalila, Han, Andrew W, Jain, Mohit, Johnson, Andrew MF, Lee, Yun Sok, Mahmood, Nadir A, Ofrecio, Jachelle M, Olefsky, Jerrold M, Pan, Dongfeng, Riopel, Matthew, Ryan, Caitlin N, Watrous, Jeramie D, Wollam, Joshua, Xu, Yong-Jiang, Ying, Wei   +16 more
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection

Frontiers in Medicine
Endothelial dysfunction represents the critical pathophysiological mediator linking the modern epidemics of obesity, type 2 diabetes mellitus, and cardiovascular disease.
Allegra Battistoni, Linda Piras, Nicola Tartaglia, Francesco Maria Carrano, Claudia De Vitis, Emanuele Barbato   +5 more
doaj   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

Clinical Pharmacology &Therapeutics, EarlyView.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source